Background: Perfluoroalkyl substances (PFAS) are persistent synthetic chemicals that may affect components of metabolic risk through the peroxisome proliferator-activated receptor but epidemiological data remain scarce and inconsistent. Objective: To estimate associations between repeated measurements of the main PFAS in plasma and total cholesterol, triglycerides and hypertension among the control subjects from a population-based nested casecontrol study on diabetes type 2 in middle-aged women and men. 
Introduction
Increasing prevalence and clustering of cardiometabolic risk factors across age groups has been described in many areas of the world (Atlas Writing et al., 2018) . Knowledge on the potential role of specific environmental contaminants in the development of these risk factors is required to enable prevention of the high number of deaths from cardiovascular diseases (CVD) considered to be attributed to environmental contaminants (Collaborators, 2016 ).
An issue of concern is that of the per-and poly-fluoroalkyl substances (PFAS), a large group of fluorinated synthetic chemicals that Longer-chain PFAS (e.g., perfluorononane acid [PFNA] , perfluorodecanoic acid [PFDA] , perfluoroundecanoic acid [PFUnDA]) seems to be more bioaccumulative than the shorter ones (e.g., perfluorooctanoic acid [PFOA] ). Likewise, the sulfonates (e.g., perfluorohexane sulfonic acid [PFHxS] ) seem more bioaccumulative than the carboxylates of the same fluorinated carbon chain length (Conder et al., 2008) . The mean serum elimination half-lives (in years) of PFOS, PFOA, and PFHxS in humans were estimated to be 5.4, 3.8, and 8.5 years, respectively, in a highly exposed occupational cohort (24 males and 2 females) (Olsen et al., 2007) . More recently, the half-lives (in years) were 5.8 (PFOS), 1.5 (PFOA), 7.1 (PFHxS), 1.7 (PFNA), 4.0 (PFDA) and 4.0 (PFDUnDA) in~20 young females and 18 (PFOS), 1.2 (PFOA), 25 (PFHxS), 3.2 (PFNA), 7.1 (PFDA), and 7.4 (PFDUnDA) iñ 60 males and older females (Zhang et al., 2013) . PFAS have structural similarities with fatty acids and may interfere with fatty acid metabolism and lipid synthesis in the liver (Frayn et al., 1996; Pilz et al., 2006) and they activate the peroxisome proliferatoractivated receptor alpha (PPARα), expressed predominantly in the liver, heart and endothelial cells and whose endogenous ligands are fatty acids. PPARα is a major regulator of a wide variety of target genes involved in lipid metabolism (Barger and Kelly, 2000; Berger et al., 2005; Ren et al., 2009; Rosen et al., 2008) . Most studies of rodents exposed to high concentrations of PFOA, although not all (Rebholz et al., 2016) , have resulted in manifest reduction in both total cholesterol and triglycerides through altered expression of lipid metabolismrelated genes (Guruge et al., 2006; Haughom and Spydevold, 1992; Loveless et al., 2006; Martin et al., 2007) . PFAS' interference with the signaling pathways of the thyroid hormones Lau et al., 2007) -involved in energy metabolism and blood pressure regulation -might be another mechanism of action of PFAS. Moreover, PFAS exposure has been associated with oxidative stress (Liu et al., 2007; Yao and Zhong, 2005) and endothelial dysfunction (Hu et al., 2003; Qian et al., 2010) , both connected to the development of CVD.
Among the observed PFAS-associated health effect in humans, much attention has been on the increase in cholesterol (mainly for PFOA) (Fitz-Simon et al., 2013; Steenland et al., 2010; Sunderland et al., 2018; Winquist and Steenland, 2014) . Opposite effects has been observed in rodents in most studies. Epidemiological studies involving occupationally exposed workers, people living near PFAS-emitting facilities, as well as general population with lower PFAS plasma concentrations, have mainly been based on cross-sectional assessments (Chain et al., 2018) . As regards blood pressure, PFOA was associated with higher prevalence of hypertension in U.S. NHANES (Min et al., 2012) , but this was not confirmed by two subsequent prospective studies (Geiger et al., 2014b; Winquist and Steenland, 2014) and even inverse association have been reported (Christensen et al., 2016) . The hazard profile of individual PFAS could vary depending on chain length, functional groups and on species Wolf et al., 2012) . Human data on other longer-chain PFAS, introduced later than PFOA and PFOS, remain scarce (Chain et al., 2018) .
The purpose of the present study was to estimate associations between the main PFAS detected in human plasma and total cholesterol, triglycerides and hypertension, among the control subjects from a population-based nested case-control study on diabetes type 2 (DonatVargas et al., 2019) in middle-aged women and men.
Material and methods

Study design and population
The study used data and samples from the Västerbotten Intervention Programme (VIP), a sub-cohort in the Northern Sweden Health and Disease Study initiated in 1985 (Norberg et al., 2010) . Briefly, inhabitants within Västerbotten County were invited to a health examination together with a questionnaire on diet and lifestyle the year they became 40, 50 or 60 years old (until 1996 also those becoming 30 years old). The participation rate exceeded 56%, but was often around 70%, of which the vast majority (90.5%) donated blood samples for research.
The present study was originally initiated to disentangle whether persistent organic pollutants, including PFAS, were associated with risk of diabetes, applying a nested case-control study design with repeated C. Donat-Vargas et al. Environment International 124 (2019) 58-65 sampling (Donat-Vargas et al., 2019) . The study included T2D cases identified in the DiabNorth register (Rolandsson et al., 2012 ) that had donated blood samples to the biobank on at least two occasions, of which at least one prior to a diabetes diagnosis. Diabetes cases were matched (1:1) according to gender, age, sample date ( ± 90 days) and type of questionnaire at baseline examination with VIP non-diabetic participants (controls), who also donated blood samples to the biobank on at least two occasions. PFAS were measured twice in plasma of 187 T2D case-control pairs.
The analyses in the present study were limited to the controls alone (i.e., we excluded the diabetes cases) to minimize the possibility that the preclinical T2D stage of cases affected plasma PFAS concentrations and CVD risk markers. The rationale for this restriction was i) the unknown effect of the diabetes disease or its treatment on the exposure, distribution or excretion of PFAS, ii) the high use of lipid lowering and antihypertensive treatment among the diabetes cases (> 50%), iii) the significant interaction detected between PFAS levels and diabetes status (i.e., being a future T2D case or a control) for the cardiometabolic outcomes (P values for the baseline interactions between the exposure to the sum of the 6 PFAS and T2D for triglycerides, cholesterol and hypertension were < 0.05, respectively); and finally, because iv) controls are more representative of the overall source population. Therefore, we considered that the interpretation of the associations based on subjects free of diabetes was the most reliable; and the study population was restricted to the 187 controls, sampled twice. Oral/ written informed consent was obtained and the regional ethics review board approved the study.
Exposure and covariate assessment
The participants' first medical examination and blood sampling were carried out during 1990 to 2003 (baseline) and later during 2001 to 2013 (follow-up). All blood samples were collected after an 8-h overnight fasting. PFAS were measured at the National Institute for Health and Welfare in Finland, using a method based on liquid chromatography-triple quadrupole mass spectrometry (LC-MS/MS) (Koponen et al., 2013) . The limit of quantitation (LOQ) ranged from 0.15 to 1.0 ng/ml. Out of the 13 different PFAS measured in plasma, baseline and follow-up concentrations of PFOA, PFOS, PFNA and PFHxS were > LOQ (0.15 ng/ml) in all subjects. Conversely, baseline and follow-up concentrations of perfluorododecane acid (PFDoA), perfluorotridecane acid (PFTrA), perfluorotetradecane acid (PFTA), PFHxA, perfluoroheptane sulfonate (PFHpS), perfluoroheptane acid (PFHpA) and perfluorodecane sulfonate (PFDS) were < LOQ in all subjects (LOQ was 0.30 ng/ml except for PFHpS that was 1.0 ng/ml). Finally, PFDA and PFUnDA were < LOQ (0.15 ng/ml) in 26% and 42% of the subjects respectively at baseline (n = 374) and 10% and 34% (n = 374) respectively at follow-up.
Thus, ultimately, six individual PFAS were available to be properly assessed, four whose concentrations were > LOQ in all subjects (PFOS, PFOA, PFHxS and PFNA), and two (PFDA and PFUnDA) to which the corresponding LOQ/2 value was imputed in those samples where concentrations were < LOQ.
The covariates included were age, gender, education level, smoking habits, body mass index (BMI), Cambridge index for physical activity, history of certain diseases, medication, alcohol consumption, phytosterols and other validated food intakes (Johansson et al., 2001; Johansson et al., 2002) from which the healthy diet score was retrieved (Nettleton et al., 2013) .
Outcome assessment
Total cholesterol and triglycerides in plasma were analysed in a sample collected (after an 8-h overnight fasting) at the same time as the sample in which PFAS later were measured. Reflotron was used up to September 2009, and the clinical chemical laboratory after September 2009. Systolic and diastolic blood pressure were measured at baseline and at follow-up with a mercury sphygmomanometer after 5 min rest with the subject in a supine or sitting position, depending on whether it was measured before September 2009 or after, respectively. Accurate equations taking into account age and gender (developed by Umeå University, Sweden, and available from the corresponding author on reasonable requests) were applied for both lipids and blood pressure measurements to make reliable comparisons before and after 2009 (Norberg et al., 2010) . Hypertension was defined as any of: i) self-reported diagnosis, ii) use of antihypertensive drugs, or iii) measured systolic/diastolic blood pressure ≥140 or ≥90 mmHg.
Statistical analyses
To illustrate the temporal trends we estimated the median PFAS for each calendar year over the whole study period as well as the median (and corresponding interquartile range, IQR) within-person 10-year change (%) for the PFAS with all the measurements > LOD, i.e., PFOS PFOA, PFHxS and PFNA. Correlations between different PFAS were assessed using Spearman's (rho).
We assessed PFAS plasma concentrations as a continuous variable (per one standard deviation [SD] increment) and categorized them into tertiles, which relax the linearity assumption. The association between individual PFAS and each cardiometabolic outcome was first assessed i) cross-sectionally at each sampling occasion (presented as Supplemental Material). In order to improve the statistical power (minimizing type 2 error) and allow for time-dependent variables potentially linked to both PFAS exposures and outcomes, we performed as a principal examination ii) repeated measures analyses based on measurements (of PFAS, outcome variables and confounders) in the two sample occasions (at baseline and at follow-up) using generalized estimating equations (GEE), which take the over-time correlations into account. A strength of Table 2 Associations between repeated measurements (baseline and at follow-up) of PFAS plasma concentrations and total cholesterol, triglycerides and hypertension, estimated using generalized estimated equation and adjusting for confounders at both sampling occasions. Notes: Estimations are adjusted for gender, age, education, sample year, body mass index, smoking habit, alcohol consumption, physical activity and healthy diet score. Estimations of individual PFAS are not mutually adjusted due to collineraity. Subjects taking cholesterol-lowering medication were excluded from the analysis of lipids. Abbreviations: PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; PFNA, perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid; PFDA, perfluorodecanoic acid; PFUnDA, perfluoroundecanoic acid; T1: first tertile; T2: second tertile; T3: third tertile; β, beta coefficient; OR, odds ratio; CI, confidence interval; SD, standard deviation. a 1-SD increase in ng/ml is: 1.38 for PFOA, 8.62 for PFOS, 0.49 for PFNA, 0.70 for PFHxS, 0.20 for PFDA and 0.19 for PFUnDA. b Hypertension defined as any of: i) self-reported diagnosis, ii) use of antihypertensive drugs, or iii) measured systolic/diastolic blood pressure ≥140 or ≥90 mmHg. this approach is that individuals are considered as a random factor, where each individual is a cluster with the two measurements; thus, GEE includes an intra-subject factor and the effect due to time-variant differences between individuals is controlled for. When lipids were the outcome, we excluded subjects using cholesterol-lowering medication. Additionally, iii) we prospectively evaluated the average PFAS exposure (of baseline and follow-up concentrations) in relation to lipids measured at follow-up adjusting for baseline confounders. We did not prospectively assess odds of hypertension because of too few new cases in relation to baseline prevalence. Results were displayed as regression coefficients (β) and Odds Ratio (OR) with their corresponding 95% confidence intervals (CI). The goodness-of-fit of the models was checked by studying the behaviour of the residuals.
All analyses were adjusted for established risk factors (gender, age, education, sample year, BMI, smoking habits, alcohol consumption, physical activity and a healthy diet score (Nettleton et al., 2013) of cardiovascular disease and variables potentially associated with PFAS concentrations.
The level of statistical significance was set at 0.05 and all tests were two-tailed. The statistical software STATA/SE version 14.0 (Stata Corp LP, College Station, TX, USA) was used for statistical analyses.
Results
Temporal trends of PFAS over the whole study period with the averaged within person 10-year relative change for the four PFAS with all measurements > LOD are presented in Fig. 1 . PFOA and PFOS decreased by 15% (IQR: −33% to 11%) and 29% (IQR: −42 to −8%), respectively; while PFNA and PFHxS increased by 53% (IQR: 23% to 94%) and 13% (IQR: −15% to 37%), respectively. Generally, the different PFAS were low to moderately correlated (rho ≤0.33) with the exception of the correlations between PFOA-PFOS and PFNA-PFDAPFUnDA (rho 0.63-0.76) ( Table A1) . Table 1 summarizes the characteristics of the study population at both sampling occasions. In general, no major differences were observed in the main characteristics between baseline and follow-up, with the exception of age (on average, 10 years difference between samples), and the use of anti-hypertensive and cholesterol lowering drugs, which increased considerably at follow-up. Smoking had decreased and the healthy diet score improved two scores on average.
In the repeated measures analysis using GEE (Table 2) , including two measurements of exposure, outcome and confounders, we observed a clear pattern of inverse associations between all assessed PFAS and triglycerides. For PFOS, the difference of levels of triglycerides was −0.29 (95% CI: −0.50, −0.08) mmol/l when comparing tertile 3 with tertile 1 and − 0.10 (95% CI: −0.18, −0.02) mmol/l per one SD increase of PFOS. This pattern was similar for the different PFAS, categorized into tertiles or expressed as continuous variables, as well as for the separate cross-sectional assessments (see Supplemental Table A2 ). Although associations between PFAS and cholesterol were also inverse, Table 3 Prospective associations between long-term PFAS plasma concentrations a and total cholesterol and triglycerides at follow-up. Notes: Estimations are adjusted for gender, age, education, sample year, body mass index, smoking habit, alcohol consumption, physical activity and healthy diet score. Estimations of individual PFAS are not mutually adjusted due to collineraity. Subjects taking cholesterol-lowering medication have been excluded for the analysis of lipids. Abbreviations: PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; PFNA, perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid; PFDA, perfluorodecanoic acid; PFUnDA, perfluoroundecanoic acid; T1: first tertile; T2: second tertile; T3: third tertile; β, beta coefficient; OR, odds ratio; CI, confidence interval; SD, standard deviation.
a Long-term PFAS are the average of baseline and follow-up concentrations and the outcomes are measured at follow-up. b 1-SD increase in ng/ml is: 1.19 for PFOA, 7.42 for PFOS, 0.42 for PFNA, 0.79 for PFHxS, 0.18 for PFDA and 0.19 for PFUnDA.
most of them were not significant. Likewise, the observed overall nonsignificant inverse association between PFAS and hypertension using tertiles, practically disappeared when PFAS were assessed as continuous variable (1-SD increase) ( Table 2 ). In the prospective assessment (Table 3) , associations between average long-term PFAS and triglycerides at the end of the follow-up showed a similar inverse pattern, although slightly diluted as compared to the repeated measures analysis. For cholesterol, the corresponding estimations were non-significant.
Discussion
In this population-based study among a non-diabetic population, using repeated measurements of both PFAS and cardio-metabolic outcomes, overall we found no indication of any associations between PFAS and increased blood lipids -as has been suggested by some previous studies (Fitz-Simon et al., 2013; Steenland et al., 2010; Winquist and Steenland, 2014) . We observed, by contrast, that PFAS were associated with lower levels of triglycerides. For total cholesterol and hypertension, the associations were mainly non-significant.
Manufacturing and use of PFOS and PFOA led to increased concentrations in human blood from the 1970s to the mid-1990s followed by a downward trend since the early 2000s, but then, with an upward trend of other longer chain-length PFAS including PFNA, PFHxS, PFDA and PFUnDA (Paul et al., 2009 ). These temporal fluctuations were detected in our data and PFAS concentrations were analogous to those observed in other populations worldwide, including U.S. (Kato et al., 2011) , Sweden (Glynn et al., 2012) , Germany (Schroter-Kermani et al., 2013), Norway (Haug et al., 2009) , Australia (Toms et al., 2009 ), Japan and China (Jin et al., 2007) . Similarly to previous population-based studies (CDC-, 2017; Christensen et al., 2016; Eriksen et al., 2013; Fisher et al., 2013; Glynn et al., 2012; Lin et al., 2009) , in this examination, PFOS and PFOA showed the highest plasma concentrations over the study period, followed by PFHxS and PFNA and, in considerably lower concentrations, PFDA and PFUnDA.
Our findings of inverse associations between PFAS and triglycerides are in the same direction as those from animal studies, including primates (Seacat et al., 2002) , where reductions of cholesterol, but also triglycerides are the prevailing findings (Guruge et al., 2006; Haughom and Spydevold, 1992; Loveless et al., 2006; Martin et al., 2007) . This hypolipidemic effect of PFAS was, however, not observed in previous epidemiological studies, which have generally shown positive rather than inverse associations between PFAS and lipids (Frisbee et al., 2010; Steenland et al., 2010; Sunderland et al., 2018; Winquist and Steenland, 2014) . The latest report from EFSA Panel on Contaminants in the Food Chain has concluded that it is likely that associations between serum PFOS and PFOA levels and serum cholesterol are causal (Chain et al. 2018) . However, the report advocated caution (and it has been considered provisional) because i) the majority of the studies are crosssectional and the reverse causality cannot be ruled out, ii) findings in humans are not consistent with the results in experimental animals, which show a PPARa-mediated decrease in serum lipids after administration of PFOS or PFOA (at high dose); and iii) confounding by diet has not been properly addressed (Chain et al. 2018) .
We observed the strongest inverse associations between PFAS and triglycerides. These findings agree with a cross-sectional study using NHANES data from adolescent participants (12-19 yrs of age), which reported inverse associations between PFNA and metabolic syndrome (Lin et al., 2009) . In analogy, another cross-sectional study with Inuit people of Nunavik, showed cholesterol/HDL-C ratio and triglycerides levels to be inversely associated with PFOS plasma levels after adjustment for n-3 PUFAs in blood (Chateau-Degat et al., 2010) . A later crosssectional study overall found no associations between PFAS and cholesterol (Christensen et al., 2016) .
By contrast, five other cross-sectional general population studiesthree in adults (Eriksen et al., 2013; Nelson et al., 2010; Skuladottir et al., 2015) and two in adolescents (Fisher et al., 2013; Geiger et al., 2014a ) -reported statistically significant positive associations between PFAS and cholesterol concentrations in serum. Among occupationally exposed workers, three (Costa et al., 2009; Olsen et al., 2003; Sakr et al., 2007) of the four existing longitudinal studies with more than one measurement reported positive associations of PFOA and PFOS with cholesterol; and only one (Olsen et al., 2012) observed no associations of PFOA and PFOS with non-high-density lipoprotein. Only two prospective studies have been published. One of them observed that a reduction of PFOA and PFOS predicted a fall in low-density lipoprotein (LDL) cholesterol but not in triglycerides (in 560 adults living in an area with contaminated public water) (Fitz-Simon et al., 2013) . The other found a positive association between retrospectively estimated serum PFOA concentration (generated through fate, transport and exposure modeling) and self-resported hypercholesterolemia (Winquist and Steenland, 2014) . Altogether, clear conclusions cannot be drawn on PFAS and human blood lipids from previous literature, due to the conflicting observations reported and the cross-sectional nature of most of the studies. As for our data, the observed PFAS-cholesterol associations were mainly non-significant and therefore considered inconclusive.
As regards blood pressure, data remain very limited for associations with PFAS. In vitro (Qian et al., 2010) and animal (Cui et al., 2009) studies support a plausible link between PFAS and vascular injury and hypertension. Conversely, in a prospective study involving people from the state of Wisconsin (Christensen et al., 2016) , all PFAS were associated with lower odds of hypertension, although only PFNA reached statistical significance. A cross-sectional NHANES study performed in children found no association between serum levels of PFOA and PFOS and hypertension (Geiger et al., 2014b) , however, the corresponding study among adults reported positive associations between PFOA and systolic blood pressure and hypertension (Min et al., 2012) . In our data, despite observing a trend of negative associations between PFAS and hypertension, it was not possible to draw any conclusion about these observations.
Although the biological pathways affected by PFAS are uncertain, the activation of the nuclear receptor PPARα seems to be a key component mediating their possible metabolic effects (Bjork and Wallace, 2009 ). PPARα is a major regulator of the expression of lipid metabolism-related genes (Guruge et al., 2006; Haughom and Spydevold, 1992; Latruffe et al., 2000; Loveless et al., 2006) and PFAS with a chain length of C 4 -C 12 have been shown to activate PPARα with varying potencies in mice (Buhrke et al., 2013) . This PPARα-mediated mechanism may, however, differ between humans and animals. It has been observed that the mouse PPARα is more sensitive to PFAS than the human PPARα Wolf et al., 2012) , which is expressed only to 1/10 of the PPARα in rodents (Klaunig et al., 2003) . In addition to the different doses of exposure between animal and population studies, this interspecies variability could explain the discrepancies observed between PFAS' effect on lipids in laboratory animals and human studies.
Interestingly, fibrates, which exert their effect by activating PPARα, have been extensively used as hypotriglyceridemic drugs. Fibrates decrease plasma triglyceride concentrations by activating enzymes responsible for β-oxidation of long chain fatty acids, reducing triglyceride synthesis and activating lipoprotein lipase Staels et al., 1998) . However, a paradoxal increase in total or LDL-cholesterol in fibrate treated subjects is not uncommon (Pasternak et al., 1996; Turpin and Bruckert, 1996) and opposite regulation of murine and human lipid metabolism-related genes expression after treatment has been reported (Berthou et al., 1996) . In mice, genetically modified to express specific human genes (Bighetti et al., 2009) , the fibrate treatment reduced triglyceride levels independently of the lipemic phenotype, while the effect on LDL and HDL cholesterol was dependent on the genotype and the presence of certain proteins (apolipoprotein CIII and the cholesteryl ester transfer protein, CETP), which strongly affect the lipid metabolism (Bighetti et al., 2009) . These data support our main findings of an inverse association between PFAS and decreased triglyceride levels and could explain the discrepancies between human and animal studies as well as the inconsistencies within the human studies.
Any failure to fully adjust for confounding leading to biased association estimates as an alternative explanation for the conflicting results observed in human studies needs to be considered. A special emphasize should be on the diet as a common cause of both PFAS exposure and altered blood lipids. Such confounding may differ between populations. In the present population, fish, regarded as healthy food, is one source of PFAS. In other populations, food packaging containing PFAS that can leach into food may have been a source (Schaider et al., 2017) . Although, by adjusting for dietary factors such as a healthy diet score, we strived to remove such confounding (blocking the backdoor path from PFAS to the lipids via the common cause); still we cannot rule out the possibility of residual or unmeasured confounding by diet.
Some main limitations of this study need to be considered. First, the cardiometabolic risk factors were not the primary endpoint of the original nested case-control study and participants were selected to be controls in a diabetes study. To avoid any impact of the diabetes disease in the associations, we limited the analysis to the non-diabetics. This selection resulted in a smaller sample size affecting the statistical power and potentially contributing to not having reached statistical significance for some associations.
An important strength is the large number of PFAS measured in plasma at two occasions, allowing for repeated measures analysis taking into account time-varying factor impact. Moreover, the data collected including diet, anthropometric measurements and clinical parameters, allowed us to control for important potential confounders that have not been accounted for in some previous studies. Finally, data on PFAS relation to hypertension and triglycerides are limited in the literature.
Conclusion
PFAS were consistently associated with lower triglycerides in blood. We did not find any clear link with either cholesterol or hypertension. Larger studies with repeated measures are needed to strengthen these results.
